Catalent (CTLT) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Catalent (NYSE:CTLT) from a buy rating to a hold rating in a research note released on Thursday morning.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

A number of other analysts have also weighed in on CTLT. ValuEngine lowered shares of Catalent from a buy rating to a hold rating in a research note on Monday, October 2nd. Needham & Company LLC reiterated a hold rating on shares of Catalent in a research note on Monday, October 23rd. First Analysis assumed coverage on shares of Catalent in a research note on Friday, January 5th. They issued an equal weight rating for the company. Wells Fargo & Co lifted their price target on shares of Catalent from $39.00 to $43.00 and gave the stock an outperform rating in a research note on Wednesday, September 20th. Finally, Bank of America reiterated a buy rating and issued a $45.00 price target (up from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $44.44.

Catalent (CTLT) traded up $0.52 during trading hours on Thursday, hitting $42.94. 522,383 shares of the stock traded hands, compared to its average volume of 653,331. Catalent has a 12-month low of $25.72 and a 12-month high of $43.42. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The stock has a market cap of $5,650.00, a PE ratio of 49.93, a price-to-earnings-growth ratio of 2.73 and a beta of 1.41.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. During the same period last year, the company posted $0.16 EPS. Catalent’s revenue was up 23.0% on a year-over-year basis. equities research analysts expect that Catalent will post 1.47 earnings per share for the current fiscal year.

In related news, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. 361 Capital LLC raised its stake in Catalent by 18.6% during the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock valued at $2,795,000 after purchasing an additional 10,974 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock valued at $41,773,000 after purchasing an additional 210,296 shares in the last quarter. Stevens Capital Management LP purchased a new stake in Catalent during the third quarter valued at $2,475,000. Sei Investments Co. raised its stake in Catalent by 119.1% during the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after purchasing an additional 51,212 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Catalent during the second quarter valued at $23,092,000. 99.37% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Catalent (CTLT) Lowered to “Hold” at Zacks Investment Research” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/19/catalent-ctlt-lowered-to-hold-at-zacks-investment-research.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply